These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 16973419)

  • 1. Serotonergic receptors in therapeutic approaches to gastrointestinal disorders.
    Neal KB; Bornstein JC
    Curr Opin Pharmacol; 2006 Dec; 6(6):547-52. PubMed ID: 16973419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonin and its role in colonic function and in gastrointestinal disorders.
    Costedio MM; Hyman N; Mawe GM
    Dis Colon Rectum; 2007 Mar; 50(3):376-88. PubMed ID: 17195902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review article: serotonin receptors and transporters -- roles in normal and abnormal gastrointestinal motility.
    Gershon MD
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():3-14. PubMed ID: 15521849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New-generation 5-HT4 receptor agonists: potential for treatment of gastrointestinal motility disorders.
    Manabe N; Wong BS; Camilleri M
    Expert Opin Investig Drugs; 2010 Jun; 19(6):765-75. PubMed ID: 20408739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of serotonin in gastrointestinal physiology and pathology.
    Cirillo C; Vanden Berghe P; Tack J
    Minerva Endocrinol; 2011 Dec; 36(4):311-24. PubMed ID: 22322654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel therapeutic targets for enteric nervous system disorders.
    De Giorgio R; Barbara G; Furness JB; Tonini M
    Trends Pharmacol Sci; 2007 Sep; 28(9):473-81. PubMed ID: 17764756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-HT(7) receptors in the modulation of cognitive processes.
    Cifariello A; Pompili A; Gasbarri A
    Behav Brain Res; 2008 Dec; 195(1):171-9. PubMed ID: 18243350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drugs acting on serotonin receptors for the treatment of functional GI disorders.
    Tonini M; Pace F
    Dig Dis; 2006; 24(1-2):59-69. PubMed ID: 16699264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serotonin receptor subtypes and affective disorders.
    Robinson DS
    Clin Neuropharmacol; 1993; 16 Suppl 3():S1-5. PubMed ID: 8131151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roles of 5-hydroxytryptamine (5-HT) receptor subtypes in the inhibitory effects of 5-HT on C-fiber responses of spinal wide dynamic range neurons in rats.
    Liu FY; Xing GG; Qu XX; Xu IS; Han JS; Wan Y
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1046-53. PubMed ID: 17329553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The serotonin signaling system: from basic understanding to drug development for functional GI disorders.
    Gershon MD; Tack J
    Gastroenterology; 2007 Jan; 132(1):397-414. PubMed ID: 17241888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enterochromaffin cells and 5-HT signaling in the pathophysiology of disorders of gastrointestinal function.
    Crowell MD; Shetzline MA; Moses PL; Mawe GM; Talley NJ
    Curr Opin Investig Drugs; 2004 Jan; 5(1):55-60. PubMed ID: 14983974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonin decreases generation of dopaminergic neurons from mesencephalic precursors via serotonin type 7 and type 4 receptors.
    Parga J; Rodriguez-Pallares J; Muñoz A; Guerra MJ; Labandeira-Garcia JL
    Dev Neurobiol; 2007 Jan; 67(1):10-22. PubMed ID: 17443768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The roles of dopamine and serotonin, and of their receptors, in regulating sleep and waking.
    Monti JM; Jantos H
    Prog Brain Res; 2008; 172():625-46. PubMed ID: 18772053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonin control of central dopaminergic function: focus on in vivo microdialysis studies.
    Di Matteo V; Di Giovanni G; Pierucci M; Esposito E
    Prog Brain Res; 2008; 172():7-44. PubMed ID: 18772026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single exposure to a serotonin 1A receptor agonist, (+)8-hydroxy-2-(di-n-propylamino)-tetralin, produces a prolonged heterologous desensitization of serotonin 2A receptors in neuroendocrine neurons in vivo.
    Carrasco GA; Van de Kar LD; Jia C; Xu H; Chen Z; Chadda R; Garcia F; Muma NA; Battaglia G
    J Pharmacol Exp Ther; 2007 Mar; 320(3):1078-86. PubMed ID: 17159160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serotonin1A receptors in the pathophysiology of schizophrenia: development of novel cognition-enhancing therapeutics.
    Sumiyoshi T; Bubenikova-Valesova V; Horacek J; Bert B
    Adv Ther; 2008 Oct; 25(10):1037-56. PubMed ID: 18839076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotonin and GI clinical disorders.
    Spiller R
    Neuropharmacology; 2008 Nov; 55(6):1072-80. PubMed ID: 18687345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of serotonin in the pathophysiology of the irritable bowel syndrome].
    Moskwa A; Boznańska P
    Wiad Lek; 2007; 60(7-8):371-6. PubMed ID: 18175558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-HT4 receptor agonists: similar but not the same.
    De Maeyer JH; Lefebvre RA; Schuurkes JA
    Neurogastroenterol Motil; 2008 Feb; 20(2):99-112. PubMed ID: 18199093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.